New insights into the genomic landscape of meningiomas identified FGFR3 in a subset of patients with favorable prognoses.

With a prevalence of 170 000 adults in the US alone, meningiomas are the most common primary intracranial tumors. The management of skull base meningiomas is challenging due to their complexity and proximity to crucial nearby structures. The identification of oncogenic mutations has provided further insights into the tumorigenesis of meningioma and the possibility of targeted therapy. This study aimed to further investigate the association of mutational profiles with anatomical distribution, histological subtype, WHO grade, and recurrence in patients with meningioma. Tissue samples were collected from 71 patients diagnosed with meningioma from 2008 to 2016. A total of 51 cases were skull based. Samples were subjected to targeted sequencing using a next generation customized cancer gene panel ( = 66 genes analyzed). We detected genomic alterations (GAs) in 68 tumors, averaging 1.56 ± 1.07 genomic alterations (GAs) per sample. was the most frequently altered gene (36/71 cases). Interestingly, we identified a number of mutations in non- genes, including a hotspot c.-124: G > A mutation that may be related to poor prognosis and mutations that may represent biomarkers of a favorable prognosis as reported in other cancers. We demonstrate that comprehensive genomic profiling in our population can reveal a potential new prognostic biomarkers of skull base meningioma. These mutations can enhance diagnostic accuracy and clinical decision-making. Among our findings were the identification of a mutation and the first report of mutations that may represent biomarkers for the identification of skull base meningioma patients with a favorable prognosis.